This study included a total of 20 eyes of 20 glaucoma patients, who were followed for at least 1-year after undergoing AGV implantation. In 12 eyes of 12 patients, conventional AGV (CAGV) surgery was performed, while in 8 eyes of 8 patients, ologen-augmented AGV (OAGV) implantation was performed.
The rate of complete success was significantly higher in the OAGV group (50.0%) than in the CAGV group (8.3%).
Surgeries with ologen implantation show encouraging results for patients with refractory glaucoma, specifically with respect to the achievement of complete success and the reduction of the number of IOP-lowering medications during the early hypertensive phase.
Citation: Kim et al. Comparison of 1-year outcomes after Ahmed glaucoma valve implantation with and without ologen adjuvant. BMC Ophthalmology, (2018) 18:45.
Funding: The authors reported no conflict of interest in the completion of this study.